Sichuan Kelun Pharmaceutical Co Ltd (002422)

Currency in CNY
35.47
+0.48(+1.37%)
Closed·
002422 Scorecard
Full Analysis
Has raised its dividend for 3 consecutive years
002422 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
34.5535.62
52 wk Range
25.7240.80
Key Statistics
Bid/Ask
35.46 / 35.46
Prev. Close
34.99
Open
34.88
Day's Range
34.55-35.62
52 wk Range
25.72-40.8
Volume
20.38M
Average Volume (3m)
18.62M
1-Year Change
9.59%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
002422 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
41.58
Upside
+17.22%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Sichuan Kelun Pharmaceutical Co Ltd Company Profile

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion set, dispensing and injection syringes, detained needles, nebulizer, and vacuum blood collection tubes; over-the-counter products; and APIs for treatment of cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injection. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.

Employees
21864
Market
China

Compare 002422 to Peers and Sector

Metrics to compare
002422
Peers
Sector
Relationship
P/E Ratio
22.3x28.6x−0.5x
PEG Ratio
−2.44−0.860.00
Price/Book
2.4x2.3x2.6x
Price / LTM Sales
2.8x3.2x3.2x
Upside (Analyst Target)
23.6%7.0%43.8%
Fair Value Upside
Unlock4.0%5.1%Unlock

Analyst Ratings

7 Buy
1 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 41.58
(+17.22% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.57%
Dividend Yield
2.15%
Industry Median 1.54%
Annualised payout
0.76
Paid annually
5-Years Growth
+12.42%
Growth Streak

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
0.3624 / 0.55
Revenue / Forecast
4.39B / 6.00B
EPS Revisions
Last 90 days

002422 Income Statement

FAQ

What Stock Exchange Does Kelun Pharm A Trade On?

Kelun Pharm A is listed and trades on the Shenzhen Stock Exchange stock exchange.

What Is the Stock Symbol for Kelun Pharm A?

The stock symbol for Kelun Pharm A is "002422."

What Is the Kelun Pharm A Market Cap?

As of today, Kelun Pharm A market cap is 56.41B.

What Is Kelun Pharm A's Earnings Per Share (TTM)?

The Kelun Pharm A EPS (TTM) is 1.57.

When Is the Next Kelun Pharm A Earnings Date?

Kelun Pharm A will release its next earnings report on 28 Aug 2025.

From a Technical Analysis Perspective, Is 002422 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Kelun Pharm A Stock Split?

Kelun Pharm A has split 3 times.

How Many Employees Does Kelun Pharm A Have?

Kelun Pharm A has 21864 employees.

What is the current trading status of Kelun Pharm A (002422)?

As of 18 Jul 2025, Kelun Pharm A (002422) is trading at a price of 35.47, with a previous close of 34.99. The stock has fluctuated within a day range of 34.55 to 35.62, while its 52-week range spans from 25.72 to 40.80.

What Is Kelun Pharm A (002422) Price Target According to Analysts?

The average 12-month price target for Kelun Pharm A is CNY41.57625, with a high estimate of CNY46 and a low estimate of CNY31. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +17.22% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.